Skip to main navigation Skip to search Skip to main content

The Association of Incidental Radiation Dose to the Heart Base with Overall Survival and Cardiac Events after Curative-intent Radiotherapy for Non-small Cell Lung Cancer: Results from the NI-HEART Study

  • G. M. Walls
  • , J. O'Connor
  • , M. Harbinson
  • , F. Duane
  • , C. McCann
  • , P. McKavanagh
  • , D. I. Johnston
  • , V. Giacometti
  • , J. McAleese
  • , A. R. Hounsell
  • , A. J. Cole
  • , K. T. Butterworth
  • , C. K. McGarry
  • , G. G. Hanna
  • , S. Jain

Research output: Contribution to journalArticlepeer-review

28 Downloads (Pure)

Abstract

Aims: Cardiac disease is a dose-limiting toxicity in non-small cell lung cancer radiotherapy. The dose to the heart base has been associated with poor survival in multiple institutional and clinical trial datasets using unsupervised, voxel-based analysis. Validation has not been undertaken in a cohort with individual patient delineations of the cardiac base or for the endpoint of cardiac events. The purpose of this study was to assess the association of heart base radiation dose with overall survival and the risk of cardiac events with individual heart base contours. Materials and methods: Patients treated between 2015 and 2020 were reviewed for baseline patient, tumour and cardiac details and both cancer and cardiac outcomes as part of the NI-HEART study. Three cardiologists verified cardiac events including atrial fibrillation, heart failure and acute coronary syndrome. Cardiac substructure delineations were completed using a validated deep learning-based autosegmentation tool and a composite cardiac base structure was generated. Cox and Fine–Gray regressions were undertaken for the risk of death and cardiac events. Results: Of 478 eligible patients, most received 55 Gy/20 fractions (96%) without chemotherapy (58%), planned with intensity-modulated radiotherapy (71%). Pre-existing cardiovascular morbidity was common (78% two or more risk factors, 46% one or more established disease). The median follow-up was 21.1 months. Dichotomised at the median, a higher heart base Dmax was associated with poorer survival on Kaplan–Meier analysis (20.2 months versus 28.3 months; hazard ratio 1.40, 95% confidence interval 1.14–1.75, P = 0.0017) and statistical significance was retained in multivariate analyses. Furthermore, heart base Dmax was associated with pooled cardiac events in a multivariate analysis (hazard ratio 1.75, 95% confidence interval 1.03–2.97, P = 0.04). Conclusions: Heart base Dmax was associated with the rate of death and cardiac events after adjusting for patient, tumour and cardiovascular factors in the NI-HEART study. This validates the findings from previous unsupervised analytical approaches. The heart base could be considered as a potential sub-organ at risk towards reducing radiation cardiotoxicity.

Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalClinical Oncology
Volume36
Issue number2
Early online date14 Nov 2023
DOIs
Publication statusPublished (in print/issue) - 28 Feb 2024

Bibliographical note

Publisher Copyright:
© 2023

Funding

This work was funded by an Irish Clinical Academic Training Programme Fellowship (G.M. Walls), which is supported by the Wellcome Trust and the Health Research Board (grant number 203930/B/16/Z), the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland.

FundersFunder number
Wellcome Trust
203930/B/16/Z

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Autosegmentation
    • cardiovascular disease
    • heart base
    • intensity-modulated radiotherapy
    • lung cancer
    • radiation cardiotoxicity

    Fingerprint

    Dive into the research topics of 'The Association of Incidental Radiation Dose to the Heart Base with Overall Survival and Cardiac Events after Curative-intent Radiotherapy for Non-small Cell Lung Cancer: Results from the NI-HEART Study'. Together they form a unique fingerprint.

    Cite this